[A17-55] Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2018
Commission awarded on 12.10.2017 by the Federal Joint Committee (G-BA).
Immune system and infections
Adolescents with genotype 2 or 3 chronic hepatitis C
Pretreated adolescents: hint of a non-quantifiable added benefit; treatment-naïve adolescents: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.